Denosumab Patent

This docket consolidates Biologics Price Competition and Innovation Act litigation brought by the manufacturer of the branded denosumab biologics, used to treat bone-density conditions and prevent cancer-related skeletal events, against multiple biosimilar developers seeking to bring follow-on versions to market. Centralized in the District of New Jersey in 2025, the docket brings together several of the later-filed BPCIA actions in this multi-year patent-assertion campaign, which has already produced numerous settlements with other biosimilar developers on individually negotiated market-entry terms, and carries 8 pending actions.

As with other branded-versus-biosimilar patent disputes, plaintiff-side or defense-side litigation funding is not a realistic capital conversation: both the branded manufacturer and each biosimilar-developer defendant are large, well-resourced pharmaceutical or biotechnology companies capable of funding their own litigation through to resolution.

This docket's value to a capital or intelligence desk is as a live illustration of how a single branded manufacturer manages a large, multi-year, multi-defendant patent-assertion campaign across a valuable biologic franchise: settling with some biosimilar developers on staggered negotiated entry dates while continuing to litigate against others, all under one MDL umbrella for coordinated pretrial efficiency. Criterica Capital does not treat this as an active funding target, but the settlement-sequencing pattern here is a useful reference point for understanding how comparable biosimilar patent campaigns are likely to unfold.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.